Cerbios-Pharma
Lugano, Switzerland
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (6)
○ EMA GMP
○ MHRA GMP
Quick Facts: Cerbios-Pharma
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Lugano, Switzerland
- Modalities
- ADC, HPAPI, Bioconjugation, Biologics, Oligonucleotides
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Cerbios-Pharma
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesADC, HPAPI, Bioconjugation, Biologics, Oligonucleotides
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (5 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press6 articles
Broad modality coverage (5 modalities)
Recent News 6 articles
CDMO/CMO Report: High-Potency Manufacturing - DCAT Value Chain Insights
CDMOs/CMOs Expand High-Potency API Manufacturing - DCAT Value Chain Insights
Precision Engineering Defines Next-Gen ADC - Genetic Engineering and Biotechnology News
HAS Healthcare Advanced Synthesis SA acquires Cerbios-Pharma SA to create leading international Group in the CDMO sector, backed by 65 Equity Partners - PR Newswire UK
Temasek’s 65 Equity makes Europe foray with Swiss pharma merger - The Straits Times
PE taps into CDMO market’s ‘strong growth’: 7 deals - pehub.com
Frequently Asked Questions About Cerbios-Pharma
What is Cerbios-Pharma's CDMO Signal Score?
Cerbios-Pharma has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Cerbios-Pharma for a manufacturing program?
Use the free AI matchmaker to compare Cerbios-Pharma against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Abzena
San Diego, CA; Bristol, PA; Cambridge, UK
Signal Score: 64.0
ADC, AOC, RDC, PDC, DAC, Fusion Proteins, Bispecifics, bsAbs, Multispecifics, msAbs, Bioconjugates, Biologics, mAb, Monoclonal Antibody, Antibodies, Cytokines, HPAPI, Bioconjugation
PCI Pharma Services
Philadelphia, PA
Sterile fill-finish, Prefilled syringes, Cartridges, Vials, Lyophilization, ADC fill-finish, HPAPI, mRNA, Biologics, Oligonucleotides, Peptides
Sai Life Sciences
Hyderabad, India
Small Molecule API, Complex Small Molecules, HPAPI, ADC, Peptides, Oligonucleotides, Lipids / LNP, Intermediates, Drug Discovery (CRO)
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
Signal Score: 83.6
Biologics, ADC
Altruist Biologics
Suzhou, China
Biologics, mAb, Bispecific/Multispecific Antibodies, Fusion Proteins, Recombinant Proteins, ADC, Cell Therapy, Gene Therapy